GlassScriptPhysician profile
Paul Guidos
NPI 1982018776
$5,087.12
in general payments reported to CMS, 2019-2025
36 companies · $41.96 in 2025
The $41.96 reported for 2025 was less than what a typical Urology provider received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $157 · 2020: $308 · 2021: $508 · 2022: $2,853 · 2023: $652 · 2024: $567 · 2025: $41.96.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,261.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,260.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teleflex LLC | $1,971.23 | 2022-2024 | Urolift |
| Boston Scientific Corporation | $450.31 | 2019-2023 | Spaceoar Vue System - 10ml |
| Endo Pharmaceuticals INC. | $409.20 | 2021-2024 | Xiaflex, Aveed |
| Antares Pharma, INC. | $332.56 | 2020-2023 | Nocdurna, Xyosted, Tlando |
| Intuitive Surgical, INC. | $216.19 | 2022-2023 | Da Vinci Surgical System |
| Abbvie INC. | $190.36 | 2020-2024 | |
| Astellas Pharma US INC | $152.95 | 2020-2022 | |
| Procept Biorobotics Corporation | $146.20 | 2024 | Aquabeam System |
| Pfizer INC. | $133.41 | 2024 | |
| C. R. Bard, INC. & Subsidiaries | $113.72 | 2020-2023 | Bard Urinary Drainage Bag |
| Dendreon Pharmaceuticals LLC | $79.33 | 2021-2022 | |
| Blue Earth Diagnostics | $77.65 | 2021-2023 | |
| Rochester Medical Corporation | $76.14 | 2022 | |
| Lundbeck LLC | $70.73 | 2021-2023 | Rexulti |
| Myriad Genetic Laboratories, INC. | $70.41 | 2021 |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tela Bio, INC. | $55.55 | 2022 | |
| Coloplast Corp | $54.69 | 2021-2022 | |
| Convatec INC. | $49.62 | 2020-2021 | |
| Tolmar, INC. | $45.94 | 2023 | |
| Tolmar Pharmaceuticals, INC. | $39.32 | 2022 | |
| Allergan, INC. | $37.09 | 2022 | |
| Olympus America INC. | $35.02 | 2021-2022 | |
| Axonics, INC. | $31.82 | 2022-2024 | Axonics |
| Sumitomo Pharma America, INC. | $29.63 | 2024 | Gemtesa |
| 180 Medical, INC. | $28.65 | 2020-2022 | |
| Neurocrine Biosciences, INC. | $24.42 | 2024 | Ingrezza |
| Boehringer Ingelheim Pharmaceuticals, INC. | $21.30 | 2025 | Jardiance |
| Progenics Pharmaceuticals, INC. | $21.23 | 2022 | |
| Endo USA, INC. | $20.66 | 2025 | Xiaflex |
| Neotract INC. | $16.77 | 2020 | |
| Genentech USA, INC. | $16.31 | 2023 | Enspryng, Ocrevus |
| Urovant Sciences INC | $15.21 | 2021 | |
| Photocure INC | $15.20 | 2023 | Cysview |
| Clarus Therapeutics INC. | $13.17 | 2021 | |
| Baudax Bio INC. | $13.12 | 2021 | |
| Janssen Biotech, INC. | $12.01 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Paul Guidos listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.